Device Radiology

Swiftninja Sterble Cor Micro

Payments companies reported to CMS as associated with Swiftninja Sterble Cor Micro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$56Kassociated payments (2023-2025)
47clinicians with associated payments
1company reporting

By year

2023 $640
2024 $17K
2025 $39K

Payments reported as associated with Swiftninja Sterble Cor Micro, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular & Interventional Radiology $51K
Diagnostic Radiology $4,870
Anesthesiology $131
Vascular Surgery $20.58
Surgery $20.58

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Swiftninja Sterble Cor Micro

These are the largest totals companies reported as associated with Swiftninja Sterble Cor Micro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Alexander Misono Newport Beach, CA Vascular & Interventional Radiology $26,399.66
Jason Hoffmann Philadelphia, PA Vascular & Interventional Radiology $9,923.19
Christopher Granville Forest City, PA Diagnostic Radiology $2,211.37
Shelby Bennett Albuquerque, NM Diagnostic Radiology $1,489.73
Malwinder Singha Rancho Cucamonga, CA Vascular & Interventional Radiology $1,266.79
Abhijit Salaskar Syracuse, NY Vascular & Interventional Radiology $1,259.48
Sudheer Paruchuri Oak Park, IL Vascular & Interventional Radiology $1,209.89
Senthil Palaniappun Oklahoma City, OK Vascular & Interventional Radiology $1,092.29
Diljot Dhillon Paramus, NJ Vascular & Interventional Radiology $1,062.89
Akram Sadeghi Dallas, TX Vascular & Interventional Radiology $1,040.56

Prescribed Swiftninja Sterble Cor Micro?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.